Mizuho Kittaka

Dr. Mizuho Kittaka

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2023 in Journal of Bone and Mineral Research
Verified
Journal Article
Open access
MKMizuho Kittaka
Mizuho Kittaka
TYTetsuya Yoshimoto
Tetsuya Yoshimoto
MLMarcus E Levitan
Marcus E Levitan
RURina Urata
Rina Urata
RCRoy B Choi
Roy B Choi
YUYasuyoshi Ueki
Yasuyoshi Ueki
Mouse ligature-induced periodontitis (LIP) has been used to study bone loss in periodontitis. However, the role of osteocytes in LIP remains unclear. Furthermore, there is no consensus on the choice of alveolar bone parameters and time points to evaluate LIP. Here, we investigated the dynamics of changes in osteoclastogenesis and bone volume (BV) loss in LIP over 14 days. Time-course analysis revealed that osteoclast induction peaked on days 3 and 5, followed by the peak of BV loss on day 7. Notably, BV was restored by day 14. The bone formation phase after the bone resorption phase was suggested to be responsible for the recovery of bone loss. Electron microscopy identified bacteria in the osteocyte lacunar space beyond the periodontal ligament (PDL) tissue. We investigated how osteocytes affect bone resorption of LIP and found that mice lacking receptor activator of NF-κB ligand (RANKL), predominantly in osteocytes, protected against bone loss in LIP, whereas recombination activating 1 (RAG1)-deficient mice failed to resist it. These results indicate that T/B cells are dispensable for osteoclast induction in LIP and that RANKL from osteocytes and mature osteoblasts regulates bone resorption by LIP. Remarkably, mice lacking the myeloid differentiation primary response gene 88 (MYD88) did not show protection against LIP-induced bone loss. Instead, osteocytic cells expressed nucleotide-binding oligomerization domain containing 1 (NOD1), and primary osteocytes induced significantly higher Rankl than primary osteoblasts when stimulated with a NOD1 agonist. Taken together, LIP induced both bone resorption and bone formation in a stage-dependent manner, suggesting that the selection of time points is critical for quantifying bone loss in mouse LIP. Pathogenetically, the current study suggests that bacterial activation of osteocytes via NOD1 is involved in the mechanism of osteoclastogenesis in LIP. The NOD1-RANKL axis in osteocytes may be a therapeutic target for bone resorption in periodontitis. © 2023 The Authors. Journal of Bone and Mineral Research published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research (ASBMR).

15 September 2017 in Journal of Bone and Mineral Research
Verified
Journal Article
Open access
PDF file
MKMizuho Kittaka
Mizuho Kittaka
KMKotoe Mayahara
Kotoe Mayahara
TMTomoyuki Mukai
Tomoyuki Mukai
TYTetsuya Yoshimoto
Tetsuya Yoshimoto
TYTeruhito Yoshitaka
Teruhito Yoshitaka
YUYasuyoshi Ueki
Yasuyoshi Ueki
Currently, it is believed that osteoclasts positive for tartrate‐resistant acid phosphatase (TRAP+) are the exclusive bone‐resorbing cells responsible for focal bone destruction in inflammatory arthritis. Recently, a mouse model of cherubism (Sh3bp2KI/KI) with a homozygous gain‐of‐function mutation in the SH3‐domain binding protein 2 (SH3BP2) was shown to develop auto‐inflammatory joint destruction. Here, we demonstrate that Sh3bp2KI/KI mice also deficient in the FBJ osteosarcoma oncogene (c‐Fos) still exhibit noticeable bone erosion at the distal tibia even in the absence of osteoclasts at 12 weeks old. Levels of serum collagen I C‐terminal telopeptide (ICTP), a marker of bone resorption generated by matrix metalloproteinases (MMPs), were elevated, whereas levels of serum cross‐linked C‐telopeptide (CTX), another resorption marker produced by cathepsin K, were not increased. Collagenolytic MMP levels were increased in the inflamed joints of the Sh3bp2KI/KI mice deficient in c‐Fos. Resorption pits contained a large number of F4/80+ macrophages and genetic depletion of macrophages rescued these erosive changes. Importantly, administration of NSC405020, an MMP14 inhibitor targeted to the hemopexin (PEX) domain, suppressed bone erosion in c‐Fos‐deficient Sh3bp2KI/KI mice. After activation of the NF‐κB pathway, macrophage colony‐stimulating factor (M‐CSF)‐dependent macrophages from c‐Fos‐deficient Sh3bp2KI/KI mice expressed increased amounts of MMP14 compared with wild‐type macrophages. Interestingly, receptor activator of NF‐κB ligand (RANKL)‐deficient Sh3bp2KI/KI mice failed to show notable bone erosion, whereas c‐Fos deletion did restore bone erosion to the RANKL‐deficient Sh3bp2KI/KI mice, suggesting that osteolytic transformation of macrophages requires both loss‐of‐function of c‐Fos and gain‐of‐function of SH3BP2 in this model. These data provide the first genetic evidence that cells other than osteoclasts can cause focal bone destruction in inflammatory bone disease and suggest that MMP14 is a key mediator conferring pathological bone‐resorbing capacity on c‐Fos‐deficient Sh3bp2KI/KI macrophages. In summary, the paradigm that osteoclasts are the exclusive cells executing inflammatory bone destruction may need to be reevaluated based on our findings with c‐Fos‐deficient cherubism mice lacking osteoclasts. © 2017 American Society for Bone and Mineral Research.

17 October 2025 in Journal of Periodontology
Verified
Journal Article
Closed access
SKSu Jung Kim
Su Jung Kim
CBChandni Batra
Chandni Batra
HYHiroki Yoshii
Hiroki Yoshii
YHYusuke Hamada
Yusuke Hamada
YUYasuyoshi Ueki
Yasuyoshi Ueki
MKMizuho Kittaka
Mizuho Kittaka

5 December 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
JCJingwen Cai
Jingwen Cai
CDCaroline Dudish
Caroline Dudish
AMAmani Mouna
Amani Mouna
AJAngelena Jacob
Angelena Jacob
WJWesley James
Wesley James
stephen hsustephen hsu
stephen hsu
Nutraceuticals such as curcumin, resveratrol, lycopene, lutein, and coenzyme Q10 pos-sess strong antioxidant and anti-inflammatory activities but their practical use is hin-dered by poor solubility and bioavailability. Traditional nanocarriers like liposomes, nanoemulsions, and polymeric nanoparticles often rely on surfactants and synthetic or-ganic solvents that limit safety, scalability, and regulatory acceptance. The present study evaluated the Facilitated Self-Assembling Technology (FAST) platform as a clean-label al-ternative for generating bioavailable nutraceutical nanoparticles. Using only food-grade facilitating medium, FAST enabled spontaneous formation of stable, amorphous nano-particles with strong negative surface charge and high colloidal stability. Hybrid nano-particles combining epigallocatechin-3-gallate-palmitates (EC16), curcumin, and resvera-trol further improved surface charge, reduced size range, and exhibited enhanced stability under simulated gastric conditions. All formulations demonstrated excellent biocompati-bility in XTT assays, with no reduction in viability compared to control. Fluorescent im-aging of EC16/Cy5 fluorescent hybrid nanoparticles confirmed nanoparticle–cell surface interactions without cytotoxicity. Compared with chemical conjugation and lipid-based nanoencapsulation, FAST offered faster, surfactant-free, and energy-efficient production, fully compliant with FDA generally recognized as safe (GRAS) standards. These results support the FAST platform as an efficient, economical, and scalable nanotechnology for next-generation functional beverages and oral nutraceutical delivery systems that meet both regulatory and consumer demands for natural, sustainable innovation.